| Filed On | Filing |
|---|---|
| 13 Nov 2023 |
8-K/A: Financial Statements and Exhibits
On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”) (a subsidiary of Bausch Health Companies Inc. (the “Company”)), Bausch + Lomb Ireland Limited (“Buyer”), entered into a Stock and Asset P... |
| 29 Sep 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In connection with his appointment as interim Chief Financial Officer, Mr. Barresi will be entitled to receive: (i) a bi-weekly cash stipend of $5,000, which will be paid in addition to his regular base pay during the time he serves in t... |
| 15 Mar 2016 |
8-K/A: Results of Operations and Financial Condition
/C O R R E C T I O N — Valeant Pharmaceuticals International, Inc./ |
| 21 Oct 2013 |
8-K/A: Financial Statements and Exhibits
The accompanying unaudited interim consolidated financial statements of Bausch & Lomb Holdings Incorporated and Consolidated Subsidiaries (“Bausch & Lomb” or “the Company”) have been prepared by the Company in accordance with the account... |
| 18 Jun 2013 |
8-K/A: Other Events
The unaudited pro forma condensed combined statements of loss for the fiscal year ended December 31, 2012 and for the three months ended March 31, 2013 are prepared by Valeant Pharmaceuticals International, Inc. (“Valeant”) and give effe... |
| 17 Jun 2013 |
8-K/A: Other Events
The unaudited pro forma condensed combined statements of loss for the fiscal year ended December 31, 2012 and for the three months ended March 31, 2013 are prepared by Valeant Pharmaceuticals International, Inc. (“Valeant”) and give effe... |
| 17 Jun 2013 |
8-K/A: Other Events
The unaudited pro forma condensed combined statements of loss for the fiscal year ended December 31, 2012 and for the three months ended March 31, 2013 are prepared by Valeant Pharmaceuticals International, Inc. (“Valeant”) and give effe... |
| 25 Feb 2013 |
8-K/A: Financial Statements and Exhibits
The unaudited pro forma condensed combined statements of income for the fiscal year ended December 31, 2011 and for the nine months ended September 30, 2012 are prepared by Valeant Pharmaceuticals International, Inc. (“Valeant”) and give... |
| 17 Feb 2012 |
8-K/A: Completion of Acquisition or Disposition of Assets
The unaudited pro forma condensed combined statements of income for the fiscal year ended December 31, 2010 and for the nine months ended September 30, 2011 combine the historical consolidated statements of income of Valeant Pharmaceutic... |
| 14 Mar 2011 |
8-K/A: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K/A dated March 14, 2011, of Valeant Pharmaceuticals International, Inc. and are in agreement with the statements contained therein. |
| 02 Mar 2011 |
8-K/A: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K/A dated March 2, 2011, of Valeant Pharmaceuticals International, Inc. and are in agreement with the statements contained therein. |
| 08 Dec 2010 |
8-K/A: Financial Statements and Exhibits
Unaudited Pro Forma Condensed Consolidated Financial Information of Valeant Pharmaceuticals International, Inc. |
Loading...